Biopharma companies are intensifying adoption of digital transformation and AI to enhance manufacturing efficiency and drug discovery. Experts caution the need for critical education to prevent AI overhyping and misuse. Additionally, pharma firms including Abbvie, J&J, Bristol Myers Squibb, Takeda, and Astex have pooled proprietary structural data to train large language models, bolstering AI capabilities in drug discovery. Meanwhile, new software tools like Giotto Suite and COOKIE-Pro provide integrated spatial omics and covalent inhibitor kinetics profiling to accelerate biomedical research.